FDA wants more time to review diabetes drug Onglyza

AstraZeneca P.L.C. and Bristol-Myers Squibb Co. said today that the U.S. Food and Drug Administration decided it needs more time to finish reviewing the companies' new drug application for Onglyza for the treatment of type 2 diabetes.